Prevention of Human Papillomavirus (HPV) and Vaccination

Dear Colleagues,

Human Papillomavirus (HPV) infection can result in cancers in both female and male populations, which could have been prevented by immunization. A secondary form of HPV cervical cancer prevention is also available. The WHO has set goals to reduce the average cervical cancer incidence rate by 10% by 2030, achieving 90% HPV vaccination coverage in girls, 70% screening coverage, and 90% coverage in terms of the treatment of precancerous lesions and invasive cancers. Different HPV vaccination and screening programs are in place worldwide. However, adherence to these preventive activities is frequently suboptimal, with some reports of vaccine hesitancy. The promotion of vaccination and screening is thus needed. Lastly, the assessment of the impact of immunization and screening could be useful to improve vaccination coverage.

This Special Issue aims to provide evidence regarding HPV vaccination and screening results and impact in different countries and settings (adolescents, healthy and treated women, men, MSM, etc.).

In this Special Issue, original research articles and reviews are welcome on research areas that may include (but are not limited to) the following: HPV genotype distribution in different pathologies according to age and sex, current and future HPV vaccination and screening strategies, efficacy and effectiveness of HPV vaccines in different target populations, measurement of HPV vaccination coverage, HPV vaccination after treatment, vaccine hesitancy, strategies to improve HPV vaccination and screening coverage in different target populations, cost-effectiveness of HPV vaccination and screening, and the use of potentially new and simplified diagnostic tests to evaluate preventive programs’ performance.

We look forward to receiving your contributions.

Dr. Sara Boccalini
Prof. Dr. Paolo Bonanni
Dr. Angela Bechini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.